SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential, djmurdock
Search This Board: 
Last Post: 5/25/2017 9:46:29 AM - Followers: 50 - Board type: Free - Posts Today: 1


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE
Current Price
Volume:
Bid Ask Day's Range
ZYNE News: Cannabis-Based Therapies with Potential to Dull the Pain of Opioid Abuse 05/17/2017 08:45:00 AM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 05/16/2017 08:51:59 AM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 05/16/2017 08:51:32 AM
ZYNE News: Quarterly Report (10-q) 05/09/2017 04:20:09 PM
ZYNE News: Current Report Filing (8-k) 05/09/2017 07:31:21 AM
PostSubject
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#593   Here we go. First NEJ publication and buyout surfgreen 05/25/17 09:46:28 AM
#592   https://www.forbes.com/sites/debraborchardt/2017/01/26/cannabis-drug-company-zyn djmurdock 05/24/17 12:52:21 PM
#591   https://www.tickerreport.com/banking-finance/2579353/granite-point-capital-manag djmurdock 05/24/17 12:51:55 PM
#590   Sounds about right. Can't wait for July/Aug djmurdock 05/24/17 12:34:05 PM
#589   Looks like manipulation and loading for summer results. surfgreen 05/24/17 12:28:15 PM
#588   Not hyped on this downtrend. djmurdock 05/24/17 11:35:35 AM
#587   Let's hold this 20$ level and never look back! $zyne Cbdpotential 05/17/17 02:57:31 AM
#586   Put me in Coach!!! (: (: Nice catch, djmurdock 05/16/17 10:08:17 PM
#585   Your right that day the stock was trading RigorousGains 05/16/17 05:57:48 PM
#584   The bought millions @18 a few months back surfgreen 05/16/17 05:56:23 PM
#583   I need couple millions to feel confident at RigorousGains 05/16/17 05:48:43 PM
#582   Agreed! Like everything I see: 5 phase 3's massive surfgreen 05/16/17 03:16:48 PM
#581   More insider purchases at $19.70-80! About $200,000 worth! CoachMarc 05/16/17 02:00:03 PM
#580   It's going to be a fun ride! a surfer 05/16/17 09:21:35 AM
#579   Agreed! Summer is gonna rock surfgreen 05/15/17 10:37:42 AM
#578   http://ir.zynerba.com/phoenix.zhtml?c=253915&p=irol-newsArticle&ID=2271219 As djmurdock 05/14/17 08:30:30 PM
#577   The manipulation even on the Nasdaq is unbelievable. surfgreen 05/10/17 03:09:11 PM
#576   Zyne is my biggest holding, so days like djmurdock 05/09/17 02:52:03 PM
#575   Surprised this dropped so low. Should gain steam surfgreen 05/09/17 12:49:05 PM
#574   $ZYNE hoping to get back to $22 this week. djmurdock 05/08/17 10:46:41 AM
#573   Thanks for the under $20 cheapies! Swoooop! djmurdock 05/03/17 12:36:23 PM
#572   Zynerba management to meet with Jefferies Meeting to djmurdock 05/02/17 01:09:41 AM
#571   Here we go again. So ez a blind surfgreen 05/01/17 02:08:18 PM
#570   Whew, looks like we found some support at $21. djmurdock 04/27/17 12:47:38 PM
#569   Can July or August hurry up (: djmurdock 04/26/17 12:56:15 PM
#568   Already own it. Agree mega potential. surfgreen 04/25/17 03:21:33 PM
#567   Gave you ZYNE a year ago at $7, biotechnician 04/25/17 03:03:58 PM
#566   Could see 20$ But I doubt it... Looking strong imo :-D Cbdpotential 04/24/17 01:04:20 PM
#565   Added 22.08$ $ZYNE Cbdpotential 04/24/17 01:03:31 PM
#564   Reload time $ZYNE$ surfgreen 04/24/17 11:15:56 AM
#563   Easily WolfOfGrnStreet 04/16/17 05:10:30 PM
#562   I think we see $40 at least when djmurdock 04/16/17 04:12:47 PM
#561   $75-$100 by the EOY IMO SYNTHETIC WINS in WolfOfGrnStreet 04/16/17 12:48:11 AM
#560   Sky is the limit with ZYNE. Adding more. WolfOfGrnStreet 04/12/17 03:05:46 PM
#559   ZYNE is Smokin! The Strongest Biotech Sector Stock bratby 04/12/17 05:47:37 AM
#558   Yes sir! WolfOfGrnStreet 04/11/17 08:33:28 PM
#557   Won't be long... I keep adding. This a surfer 04/11/17 04:09:25 PM
#556   GWPH Who? WolfOfGrnStreet 04/10/17 07:52:15 PM
#555   Looks like someone in on the know is djmurdock 04/10/17 05:26:11 PM
#554   ZYNE is on ETF, and OWCP will be Up 4 Air 04/10/17 05:19:57 PM
#553   ZYNE is listed on the newly released Horizon's Up 4 Air 04/10/17 05:17:58 PM
#552   Charts show move to $44 before any big resistence. biotechnician 04/10/17 03:36:32 PM
#551   12% something is up! a surfer 04/10/17 02:43:06 PM
#550   Holy crap! Nice day...haven't seen any news BigD_McGee 04/10/17 01:25:49 PM
#549   Nice move today $zyne Cbdpotential 04/07/17 07:01:34 PM
#548   Amen! a surfer 04/07/17 03:51:01 PM
#547   We're looking good here! Could be explosive in July/August djmurdock 04/07/17 01:38:08 PM
#546   $ZYNE$ Stairway to heaven surfgreen 04/07/17 11:14:00 AM
#545   It took a breather around $20 for a CoachMarc 04/06/17 02:27:47 PM
#544   Looking good today $zyne Cbdpotential 04/06/17 11:25:50 AM
PostSubject